Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q2 2022 · 10-Q
Revenue—
Net Income$16.01M$16.01MN/M vs Q2 2021 EPS Diluted$0.04$0.04N/M vs Q2 2021 Operating Income-$256,315N/M Operating Cash Flowderived-$203,131N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 22, 2022 · 53 d after period end